Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

OptimizeRx (OPRX) Net Cash Flow (2016 - 2025)

OptimizeRx's Net Cash Flow history spans 16 years, with the latest figure at $2.9 million for Q3 2025.

  • For Q3 2025, Net Cash Flow rose 151.41% year-over-year to $2.9 million; the TTM value through Sep 2025 reached $3.4 million, down 45.31%, while the annual FY2024 figure was -$472000.0, 89.17% up from the prior year.
  • Net Cash Flow for Q3 2025 was $2.9 million at OptimizeRx, up from $12000.0 in the prior quarter.
  • Across five years, Net Cash Flow topped out at $71.8 million in Q1 2021 and bottomed at -$46.1 million in Q3 2022.
  • The 5-year median for Net Cash Flow is $115000.0 (2023), against an average of $473784.7.
  • The largest annual shift saw Net Cash Flow surged 2070.07% in 2021 before it tumbled 6068.58% in 2022.
  • A 5-year view of Net Cash Flow shows it stood at -$374808.0 in 2021, then crashed by 6068.58% to -$23.1 million in 2022, then surged by 117.0% to $3.9 million in 2023, then plummeted by 169.87% to -$2.7 million in 2024, then skyrocketed by 206.85% to $2.9 million in 2025.
  • Per Business Quant, the three most recent readings for OPRX's Net Cash Flow are $2.9 million (Q3 2025), $12000.0 (Q2 2025), and $3.2 million (Q1 2025).